Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

NCT05409261 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

200

Enrollment

OTHER_GOV

Sponsor class

Conditions

COVID-19
Vaccine Reaction
SARS CoV 2 Infection
Vaccine Adverse Reaction

Interventions

BIOLOGICAL: Ad26.COV2.S

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]